Apr 18, 2023 · Overall, the study demonstrates that A166 has manageable toxicity, good stability in circulation, and promising antitumour activities in HER2- ...
It demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer. Clinical ...
People also ask
What are the results of NCT03602079?
Apr 18, 2023 · A166 has a recommended phase II dose of 4.8 mg/kg Q3W, manageable toxicity, good stability in the circulation and promising antitumour ...
A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site- ...
Jun 2, 2022 · Background: A166, an antibody-drug conjugate, with an anti-HER2 antibody site-specifically conjugated to Duo-5 (anti-microtubule agent), ...
May 3, 2022 · A166 is a third-generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena Biopharma's proprietary tubulin ...
Dec 1, 2019 · Purpose: A166 is an Antibody Drug Conjugate (ADC) targeting HER2-expressing cancer cells, aiming for post trastuzumab/TDM1 population and ...
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to ...
May 29, 2022 · A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti- ...
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells. Experimental: Phase II: • Cohort 2. HER2 positive ...